The rise of copyright’s blockbuster initially sparked a surge for major pharmaceutical companies, nevertheless recent changes present a complicated outlook for investors. Generic versions are eating into earnings, and ongoing legal battles add more complexity to the landscape. While some companies might still gain from adjacent services, the gen… Read More